Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT03256695. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between as-needed usage of albuterol eMDPI and Clinical Exacerbation-Chronic Obstructive Pulmonary Disease (CE-COPD) in adult participants at least 40 years of age with exacerbation-prone COPD.
Study identification
- NCT ID
- NCT03256695
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 405 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2017 (Actual)
- Primary completion
- Apr 17, 2018 (Actual)
- Completion
- Apr 17, 2018 (Actual)
- Last update posted
- Nov 9, 2021
2017 – 2018
United States locations
- U.S. sites
- 40
- U.S. states
- 17
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 14682 | Andalusia | Alabama | 36420 | — |
| Teva Investigational Site 14704 | Anniston | Alabama | 36207 | — |
| Teva Investigational Site 14712 | Mobile | Alabama | 36608 | — |
| Teva Investigational Site 14702 | Peoria | Arizona | 85381 | — |
| Teva Investigational Site 14706 | Gold River | California | 95670 | — |
| Teva Investigational Site 14720 | Waterbury | Connecticut | 06708 | — |
| Teva Investigational Site 14725 | Brandon | Florida | 33511 | — |
| Teva Investigational Site 14711 | Daytona Beach | Florida | 32117 | — |
| Teva Investigational Site 14699 | DeLand | Florida | 32720 | — |
| Teva Investigational Site 14694 | Edgewater | Florida | 32132 | — |
| Teva Investigational Site 14701 | Miami | Florida | 33126 | — |
| Teva Investigational Site 14689 | Miami | Florida | 33135 | — |
| Teva Investigational Site 14678 | Miami | Florida | 33155 | — |
| Teva Investigational Site 14688 | Orlando | Florida | 32825 | — |
| Teva Investigational Site 14679 | Valparaiso | Indiana | 46383 | — |
| Teva Investigational Site 14677 | North Dartmouth | Massachusetts | 02747 | — |
| Teva Investigational Site 14705 | Chesterfield | Missouri | 63017 | — |
| Teva Investigational Site 14717 | Omaha | Nebraska | 68114 | — |
| Teva Investigational Site 14684 | Toms River | New Jersey | 08755 | — |
| Teva Investigational Site 14710 | Charlotte | North Carolina | 28207 | — |
| Teva Investigational Site 14696 | Gastonia | North Carolina | 28054 | — |
| Teva Investigational Site 14722 | Greensboro | North Carolina | 27408 | — |
| Teva Investigational Site 14692 | Winston-Salem | North Carolina | 27103 | — |
| Teva Investigational Site 14708 | Columbus | Ohio | 43215 | — |
| Teva Investigational Site 14703 | Dayton | Ohio | 45458 | — |
| Teva Investigational Site 14680 | Grove City | Ohio | 43123 | — |
| Teva Investigational Site 14709 | Toledo | Ohio | 43617 | — |
| Teva Investigational Site 14724 | Willoughby | Ohio | 44094 | — |
| Teva Investigational Site 14683 | Pittsburgh | Pennsylvania | 15243 | — |
| Teva Investigational Site 14681 | Charleston | South Carolina | 29406 | — |
| Teva Investigational Site 14686 | Easley | South Carolina | 29640 | — |
| Teva Investigational Site 14719 | Gaffney | South Carolina | 29341 | — |
| Teva Investigational Site 14691 | Greenville | South Carolina | 29615 | — |
| Teva Investigational Site 14695 | Mt. Pleasant | South Carolina | 29464 | — |
| Teva Investigational Site 14715 | Spartanburg | South Carolina | 29303 | — |
| Teva Investigational Site 14718 | Spartanburg | South Carolina | 29303 | — |
| Teva Investigational Site 14707 | Union | South Carolina | 29379 | — |
| Teva Investigational Site 14716 | San Antonio | Texas | 78229 | — |
| Teva Investigational Site 14713 | Richmond | Virginia | 23225 | — |
| Teva Investigational Site 14687 | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03256695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03256695 live on ClinicalTrials.gov.